ESAs

Schmidt argued that the draft guidance might put a damper on usage of the anemia drugs (known as ESAs, or erythropoietin-stimulating agents) not only before kidney dialysis (a $200 million market, Schmidt says) but also after dialysis (a $2.5 billion market).

Amgen Falls On Medicare Worries Matthew Herper 2011

Dopers looking to boost their red blood cell counts use drugs called ESAs - erythropoeisis-stimulating agents.

Canadian Online Health News 2010

Dopers looking to boost their red blood cell counts use drugs called ESAs - erythropoeisis-stimulating agents.

Canadian Online Health News Helen Branswell 2010

It's never too early or too late to save for future college costs with tax-advantaged savings vehicles, including Coverdell education savings accounts (otherwise known as ESAs) and plans, which are offered by individual states.

ABC News: Top Stories 2010

The FDA acknowledged that PBI-1402 was a novel, first-in-class drug that differs, via its mechanism of action, from existing medications approved for the treatment of anemia, such as the marketed erythropoiesis-stimulating agents ( "ESAs").

Marketwire - Breaking News Releases 2010

Sales of the class of such medications—known as erythropoesis stimulating agents, or ESAs—have fallen in recent years over previous safety issues, and both Epogen and Aranesp saw sales decline in the first quarter of this year.

FDA Calls for Trimming Anemia-Drug Dosages Thomas M. Burton 2011

Schmidt wrote: "We believe certain constituencies within CMS would like to use the low confidence vote from MEDCAC to argue that ESAs are not medically useful or necessary, and that hemoglobin targets should be lowered to the lowest level possible to avoid any safety risks."

Amgen Falls On Medicare Worries Matthew Herper 2011

The drug belongs to a class of drugs called erythropoiesis-stimulating agents, or ESAs, that have come under intense scrutiny from the FDA after being linked to higher risk of cardiovascular problems and death.

Merck Move Shows Hurdles to Developing Biotech Generics 2010

It was important, claimed the parliament, that the three should be in the same place "to ease interaction between the ESAs."

EU's Rocky Regulatory Road 2010

Look forward to an FDA public advisory committee meeting sometime in 2010 to reevaluate the use of ESAs in the treatment of anemia due to chronic kidney disease. —

Reevaluate this: Drugs to boost hemoglobin need better research 2010